NCT05022030View on ClinicalTrials.gov

First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes

PHASE2RecruitingINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

July 21, 2021

Primary Completion Date

June 1, 2025

Study Completion Date

June 1, 2026

Conditions

Colo-rectal CancerCapecitabineCetuximab

Interventions

DRUG

mCapOX plus cetuximab

capecitabine 1000mg/m2 po bid d1-7+oxaliplatin ivgtt 85mg/m2 d1+cetuximab ivgtt 500mg/m2, q2w

DRUG

mFOLFOX6 plus cetuximab

oxaliplatin ivgtt 85mg/m2 d1+ leucovorin ivgtt 400mg/m2 d1+ fluorouracil iv bolus 400mg/m2 d1+ fluorouracil 2400mg/m2 continuous infusion for 46h+cetuximab ivgtt 500mg/m2, q2w

Trial Locations (1)

610041

RECRUITING

West China Hospital of Sichuan University, Chengdu

All Listed Sponsors

collaborator

First Affiliated Hospital of Chongqing Medical University

OTHER

lead

West China Hospital

OTHER

NCT05022030 - First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes | Biotech Hunter | Biotech Hunter